Xtalks Speaks with Astellas Pharma's VP & Head of BioPharma Development Marci English About Menopause Drug Approval

Xtalks Life Science Podcast

English - June 28, 2023 09:00 - 19 minutes - 13.5 MB
Life Sciences Science pharma pharmaceuticals biotech biotechnology medical device life science drug safety clinical research clinical trials drug development Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Wireless Charging for Medical Devices: Interview with Resonant Link’s CEO and Co-Founder Dr. Grayson Zulauf

Next Episode: Developing More Affordable Cellular Immunotherapies: Interview with CytoMed Therapeutics

This episode features an interview with Marci English, Vice President and Head of BioPharma Development at Astellas Pharma, about the recent FDA approval of the company’s drug Veozah (fezolinetant) for the treatment of moderate to severe hot flashes and night sweats due to menopause.

Hormone replacement therapy (HRT) has been the conventional treatment for menopause-associated vasomotor symptoms, otherwise known as hot flashes and night sweats; however, not all women can receive hormone therapies. Apart from HRT, treatment options have been limited for the vasomotor symptoms of menopause and therefore, the approval of Veozah addresses a significant unmet need in the space.

Hear more about Veozah, including its mechanism of action and the pathways to its approval.

For more life science and medical device content, visit the Xtalks Vitals homepage.

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Twitter Mentions

@xtalks